Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$18.63 +0.04 (+0.22%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$18.64 +0.01 (+0.05%)
As of 10/3/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Advanced

Key Stats

Today's Range
$18.60
$19.06
50-Day Range
$13.97
$20.26
52-Week Range
$5.14
$29.46
Volume
239,517 shs
Average Volume
491,591 shs
Market Capitalization
$1.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Moderate Buy

Company Overview

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 675th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Upstream Bio has a consensus price target of $56.50, representing about 203.3% upside from its current price of $18.63.

  • Amount of Analyst Coverage

    Upstream Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

  • Price to Book Value per Share Ratio

    Upstream Bio has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Upstream Bio's valuation and earnings.
  • Percentage of Shares Shorted

    15.13% of the float of Upstream Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Upstream Bio has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Upstream Bio has recently decreased by 2.90%, indicating that investor sentiment is improving.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.13% of the float of Upstream Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Upstream Bio has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Upstream Bio has recently decreased by 2.90%, indicating that investor sentiment is improving.
  • News Sentiment

    Upstream Bio has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for UPB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UPB Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Upstream Bio, Inc. (UPB): A Bull Case Theory
TD Cowen Remains a Buy on Upstream Bio, Inc. (UPB)
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB shares have increased by 13.3% and is now trading at $18.63.

Upstream Bio, Inc. (NASDAQ:UPB) announced its earnings results on Wednesday, August, 6th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.13. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative trailing twelve-month return on equity of 35.90%.

Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/06/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
CIK
2022626
Fax
N/A
Employees
38
Year Founded
2021

Price Target and Rating

High Price Target
$75.00
Low Price Target
$38.00
Potential Upside/Downside
+203.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.81 million
Net Margins
-3,836.58%
Pretax Margin
-3,836.58%
Return on Equity
-35.90%
Return on Assets
-26.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
38.27
Quick Ratio
38.27

Sales & Book Value

Annual Sales
$2.37 million
Price / Sales
423.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.77 per share
Price / Book
2.12

Miscellaneous

Outstanding Shares
53,910,000
Free Float
46,599,000
Market Cap
$1.00 billion
Optionable
N/A
Beta
N/A

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners